Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine
Loading...
Authors
Jiang, Yan
Huang, Zhen-Lun
Issue Date
2022-06-17
Type
Article
Language
en_US
Keywords
Menstruation , Calcitonin Gene-related Peptide , CGRP Receptors , Menstrual Migraine , Treatment
Alternative Title
Abstract
Menstrual migraine (MM) has a longer duration and higher drug resistance than non-perimenstrual migraine. Calcitonin gene-related peptide (CGRP) and CGRP receptors are expressed in the peripheral and central nervous systems throughout the trigeminovascular system. The CGRP/CGRP receptor axis plays an important role in sensory physiology and pharmacology. CGRP receptor antagonists and anti-CGRP monoclonal antibodies (mAbs) have shown consistent efficacy and tolerability in the prevention of chronic or episodic migraine and are now approved for clinical use. However, few studies have reported the use of these drugs in MM, and no specific treatment for MM has been approved. This review aimed to shed light on the recent advances in targeting calcitonin gene-related peptides for the treatment of menstrual migraines in PubMed. In this review, we first discuss the axis of the CGRP/CGRP receptor. We then discuss the role of CGRP receptor antagonists and anti-CGRP mAbs in MM treatment. Finally, we discuss the role of the combination of anti-CGRP mAbs and CGRP receptor antagonists in migraine treatment and the drugs that inhibit CGRP release. Altogether, the anti-CGRP mAbs or CGRP receptor antagonists showed good efficacy and safety in the treatment of MM.
Description
Citation
Jiang, Y., & Huang, Z. L. (2022). Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review. Medicine, 101(24), e29361. https://doi.org/10.1097/MD.0000000000029361
Publisher
Medicine